[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.176.35. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Citations 0
Correction
December 27, 2006

Incorrect Data and Omission of Trial Site and Personnel in: Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

JAMA. 2006;296(24):2926. doi:10.1001/jama.296.24.2926-a

Incorrect Data and Omission of Trial Site and Personnel: In the Original Contribution entitled “Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial” published in the June 21, 2006, issue of JAMA (2006;295:2727-2741), incorrect data were reported. In Table 2 on page 2731, the risk ratio (RR) for estrogen receptor–positive patients should have been reported as 0.94, not 0.93; in the “Invasive Breast Cancer” panel of Figure 2 on page 2732, the number at risk in the raloxifene group at 36 months should have been reported as 6702, not 6701; and in Table 5 on page 2735, the rate per 1000 for ischemic heart disease in the tamoxifen group should have been reported as 2.99, not 3.00, and the difference between the rates by treatment group should have been reported as −0.30, not −0.29. Also, a trial site and its personnel were inadvertently omitted: in the list of active NSABP STAR P-2 clinical centers appearing on page 2739, “Boston Medical Center, Boston, Mass: Marianne N. Prout (PI), Liz Pottier (PC);” should have appeared between the entries for Boca Raton Community Hospital and CAMC Health Education and Research Center.

×